Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

China Overtakes US in Cancer Drug Approvals

28 August 2026 · By · Wire by Fusion42

Published

28 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

China

◆ Source

Read at the-scientist.com →

◆ Verified

Fusion42 · 28 August 2026 · Fusion42 review

Between 2020 and 2025, China approved more new cancer drugs than the US, highlighting a shift in global drug development leadership. While the FDA reviews drugs faster, China's National Medical Products Administration has increased approvals significantly, especially in the last three years, marking an evolving competitive landscape.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Chinese cancer drug approval growth means you face new regulatory benchmarks outside the US. Expanding into China requires adapting to their faster evolving approval environment, not just competing on review speed.

◆ Coverage

1 source · 28 Aug 2026

◆ Related on Wire

◆ Topics

Biotechchinauscancer-drugsdrug-approvalregulatory-shiftbiotech